Clinical Trials Browser

Phase 3 × INDUSTRY × Cetuximab × Clear all

NCT05239741 2026-04-17

MK-3475-C66

Phase 3 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06662786 2026-04-13

OrigAMI-2

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06750094 2026-04-13

OrigAMI-3

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06997497 2026-04-13

KANDLELIT-012

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT06064877 2026-04-09

FIERCE-HN

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasm Metastasis, Recurrence

NCT05253651 2026-04-07

MOUNTAINEER-03

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04590963 2026-03-13

INTERLINK-1

Phase 3 Active not recruiting

370 enrolled 21 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT04892173 2026-03-13

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07435324 2026-02-27

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Phase 3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Phase 3 Completed

89 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04008030 2025-10-03

CheckMate 8HW

Phase 3 Active not recruiting

839 enrolled 22 charts 3 FDA

Gastrointestinal

Colorectal Neoplasms

NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Phase 3 Active not recruiting

831 enrolled 5 FDA

Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT02358031 2025-07-18

MK-3475-048

Phase 3 Completed

882 enrolled 50 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT04793958 2025-02-11

KRYSTAL-10

Phase 3 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02563002 2024-10-03

KEYNOTE-177

Phase 3 Completed

307 enrolled 16 charts 3 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT02928224 2023-12-21

BEACON CRC

Phase 3 Completed

702 enrolled 82 charts 3 FDA

Gastrointestinal

Colorectal Neoplasms

NCT02741570 2023-09-21

CheckMate 651

Phase 3 Completed

947 enrolled 19 charts

Head and Neck Neoplasms

NCT02252042 2023-07-17

MK-3475-040

Phase 3 Completed

495 enrolled 32 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Squamous Cell

NCT03391934 2023-04-05

Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer

Phase 3 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05751512 2023-03-02

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Phase 3 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT02105636 2022-10-05

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

Phase 3 Completed

361 enrolled 14 charts

Squamous Cell Carcinoma of Head and Neck

NCT01001377 2022-09-21

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Phase 3 Completed

1,010 enrolled 22 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT02383966 2022-05-13

CHANGE2

Phase 3 Completed

243 enrolled 17 charts

Squamous Cell Carcinoma of Head and Neck

NCT02551159 2021-10-13

KESTREL

Phase 3 Completed

823 enrolled 23 charts

Squamous Cell Carcinoma of Head and Neck

NCT03349710 2021-08-09

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

Phase 3 Completed

74 enrolled 19 charts

Squamous Cell Carcinoma of Head and Neck

NCT01228734 2020-01-28

TAILOR

Phase 3 Completed

553 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT03342352 2019-12-20

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Phase 3 Withdrawn

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03386838 2019-04-18

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Phase 3 Withdrawn

Head and Neck Neoplasms

NCT00252564 2019-02-15

Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer

Phase 3 Completed

247 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT03362684 2017-12-05

PETACC-8 miR-31-3p and miR-31-5p Ancillary Study

Phase 3 Completed

Gastrointestinal

Colorectal Neoplasms

NCT01309126 2017-07-13

PRIMUS

Phase 3 Terminated

Gastrointestinal

Recurrence, Colorectal Neoplasms

NCT00154102 2017-01-30

CRYSTAL

Phase 3 Completed

1,221 enrolled 24 charts

Gastrointestinal

Colorectal Neoplasms

NCT01338558 2016-11-02

A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab

Phase 3 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT00112294 2015-12-24

Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Phase 3 Completed

755 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung

NCT01012258 2015-07-09

CHANCE

Phase 3 Completed

70 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck

NCT01177956 2014-09-03

CHANGE

Phase 3 Completed

73 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck

NCT00122460 2014-07-23

Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)

Phase 3 Completed

442 enrolled 18 charts

Head and Neck Neoplasms

NCT00678535 2014-07-21

EXPAND

Phase 3 Completed

904 enrolled 12 charts

Gastrointestinal

Stomach Neoplasms

NCT00148798 2014-06-25

FLEX

Phase 3 Completed

1,861 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00820755 2014-05-05

NEXT

Phase 3 Completed

583 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT00095199 2012-10-15

Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer

Phase 3 Completed

939 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT00061815 2010-04-12

Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer

Phase 3 Completed

Gastrointestinal

Colorectal Neoplasms

NCT00063141 2010-04-12

Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

Phase 3 Completed

Gastrointestinal

Colorectal Neoplasms